Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Genoma Research Group Inc

Neither a doctor nor a teaching hospital

Research payments

$3,886,405

2,720 payments

Through program year 2025, Genoma Research Group Inc is reported as receiving $3,886,405 in research payments, across 2,720 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $390,309 51
2024 Research $517,383 45
2023 Research $785,166 606
2022 Research $1,091,027 1,957
2021 Research $200,676 18
2020 Research $438,676 21
2019 Research $463,170 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,650,741 2,582 payments
  2. Genentech, Inc. $810,861 26 payments
  3. Allergan Inc. $716,096 15 payments
  4. Novartis Pharmaceuticals Corporation $197,413 5 payments
  5. Sumitomo Pharma America, Inc. $163,389 29 payments
  6. AbbVie, Inc. $115,548 17 payments
  7. Gilead Sciences, Inc. $111,400 14 payments
  8. Myovant Sciences GmbH $45,960 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $27,448 1 payment
  10. Chiesi USA, Inc. $20,033 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $1,015,634 2,513 payments
  2. Roche Cancer Screening Collection Study $810,861 26 payments
  3. A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD $445,345 42 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $335,215 8 payments
  5. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $316,708 2 payments
  6. A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors $168,273 16 payments
  7. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $110,384 12 payments
  8. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalco $101,282 3 payments
  9. A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (Ljn452) & Licogliflozin (Lik066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (Nash) and Liver Fibrosis $94,581 1 payment
  10. M16-824 $78,695 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record